Medica Central Coverage Policy

Policy Name:	**Automated, Non-Invasive Nerve Conduction Velocity (NCV) Testing MP9689**
Effective Date:	**09/01/2025**

Important Information – Please Read Before Using This Policy

These services may or may not be covered by all Medica Central plans. Coverage is subject to requirements in applicable federal or state laws. Please refer to the member's plan document for other specific coverage information. If there is a difference between this general information and the member's plan document, the member's plan document will be used to determine coverage. With respect to Medicare, Medicaid, and other government programs, this policy will apply unless these programs require different coverage.

Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions may call the Provider Service Center. Please use the Quick Reference Guide on the Provider Communications page for the appropriate phone number. https://mo-central.medica.com/Providers/SSM-employee-health-plan-for-IL-MO-OK-providers

Medica Central coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment.

Coverage Policy

Automated, non-invasive nerve conduction velocity (NCV) testing is investigative and unproven, and therefore **NOT COVERED**. There is insufficient reliable evidence in the form of high quality peer-reviewed medical literature to establish the efficacy or effects on health care outcomes.

Note: See also related coverage policy "Quantitative Sensory Tests."

Description

Standard nerve conduction velocity tests have two parts: testing motor nerves and testing sensory nerves. Standard NCV testing is performed by a physician specialist or a registered technologist stimulating and recording both proximally and distally along normal and abnormal nerve conduction pathways. Standard NCV testing may be varied according to specific clinical factors (e.g. patient history, findings on examination or anatomy). Measurement of nerve conduction speed is commonly performed to aid in the diagnosis of various disorders affecting the nerves of the upper extremities such as diabetic neuropathy (DN) and carpal tunnel syndrome (CTS). Diseased or damaged nerves show decreased conduction speed or smaller-sized electrical signals. Standard NCV tests are done in conjunction with needle electromyography (EMG).

Automated or point-of-care nerve conduction velocity (NCV) tests are purported to evaluate the integrity or diagnose diseases of the peripheral nervous system without the complementary needle EMG. Automated devices for NCV testing may be administered by office staff to stimulate and record distally specific nerves in one direction of conduction only. Stimulator and recording sites are placed at pre-determined anatomic locations with automated devices and may not be varied according to specific clinical factors. The NC-stat device is one example of an automated hand-held non-invasive device using proprietary technology for conducting NCV testing in the point of care setting.

FDA Approval

The U.S. food and Drug Administration defines a nerve conduction velocity measurement device as “a device which measures nerve conduction time by applying a stimulus, usually to a patient’s peripheral nerve. This device includes the stimulator and the electronic processing equipment for measuring and displaying the nerve conduction time. There are 510(k) clearances for devices or modifications to devices measuring nerve conduction velocity. Examples include, but not are limited to:

- NC-stat® (NeuroMetrix) received FDA clearance (K060584) on July 26, 2006.
- XLTEK NeuroPath (Excel-Tech Ltd.) received FDA clearance (K053058) on February 7, 2006.
- BREVIO (Neurotron) received FDA clearance (K012069) on August 1, 2001.
- VT3000 (Virtual Medical Systems Boxborough, MA) received FDA clearance (K052904) on October 27, 2005.
- XLTEK Neuropath (Excel-Tech, Ontario, Canada) received FDA clearance (K053058) on February 7, 2006

Prior Authorization

Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.

Coding Considerations

Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

CPT Code:

- **95905** - Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report

Medica Central Coverage Policy

	Committee/Source	Date(s)
Document Created:	Medical Policy Committee/Health Services Division	December 20, 2023
Revised:	Medical Policy Committee/Health Services Division	February 21, 2024
	Medical Policy Committee/Health Services Division	July 17, 2024
Reviewed:	Medical Policy Committee/Health Services Division	February 21, 2024
	Medical Policy Committee/Health Services Division	July 17, 2024

Original Effective Date:	01/01/2024
Re-Review Date(s):	04/17/2025

Administrative Update(s):